Proviva Therapeutics

Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a Series A financing round led by Lapam Capital, Ennovation Ventures, and Sangel Capital. The funds raised will be directed towards the clinical advancement of the company’s core product, PTX-912. Specializing in the development of next-generation…